Tirzepatide characterization: helicity, charge variants & dual-pathway potency
Tirzepatide is a 39-amino-acid dual GIP/GLP-1 receptor agonist carrying a C20 fatty-diacid side chain at Lys20 (γ-Glu–2×AEEA linker) and two Aib residues (Aib2, Aib13) that stabilize its α-helical conformation. Its size, lipidation and dual pharmacology demand a fully orthogonal characterization package.
What each method answers for tirzepatide
Obtain a c(s) sedimentation coefficient distribution under selected formulation and concentration conditions. Report relative signals for resolved groups and compare with SEC when relevant.
Compare far-UV CD spectra and estimate secondary structure where applicable. Near-UV fingerprints and apparent transition temperatures depend on signal quality and interpretable transitions.
Determine apparent pI and relative peak areas for resolvable species. Assigning a peak to a particular charge variant requires a reference material or independent structural evidence.
Report dose–response curves and EC50 separately for GLP-1R / GIPR. Relative potency against a reference may be calculated when the comparison criteria for each receptor assay are met.
Tirzepatide impurity library
The catalog covers synthesis and degradation-related impurities. Confirm specifications, batch documentation, availability and lead time for the requested item.
- [D-Tyr1]Tirzepatide
- [β-Asp9]Tirzepatide
- [β-Asp15]Tirzepatide
- [D-β-Asp15]Tirzepatide
- [Des γ-Glu(Side Chain)]-Tirzepatide
- [Double Tyr1]Tirzepatide
- [Des- Tyr1-Aib2]-Tirzepatide
- [Des-Pro36-Pro37]Tirzepatide
Tirzepatide characterization — common questions
How do you demonstrate dual GIP/GLP-1 agonist activity?+
We run the sample on two stable reporter cell lines — GLP-1R CRE-luciferase and GIPR CRE-luciferase — in parallel. Each yields EC50 and relative potency against the reference standard; the ratio between pathways characterizes the activation bias and detects batch-to-batch drift.
Which quality attributes are most critical for tirzepatide?+
Helical conformation (Aib2/Aib13 stabilized — verified by CD), lipidation integrity (side-chain variants tracked via impurity standards), charge heterogeneity from deamidation and Asp9/Asp15 isomerization (cIEF), and the solution-state aggregation profile (SV-AUC).
Which tirzepatide impurities does your library cover?+
123 standards: D-epimers such as [D-Tyr1]Tirzepatide, β-Asp and D-β-Asp isomers at positions 9 and 15, deletion and insertion (double-residue) sequences, and side-chain linkage variants — for ICH Q3A/Q3B impurity control and ICH Q2 method validation.
Can you support a tirzepatide comparability study?+
Yes — test article vs. reference product side by side: c(s) aggregation profiles, CD spectra and Tm, cIEF variant ratios, and dual-receptor relative potency, reported as an integrated ICH Q5E comparability package.
How much sample do the four methods consume?+
The full orthogonal panel typically requires only a few milligrams of peptide in total; all four methods share one sample set. We confirm exact consumption against your concentration and formulation in the analytical plan.
Working on tirzepatide development or a generic program?
Tell us your molecule and regulatory target — we return a tailored orthogonal characterization plan within 2 business days.